News from nuvation bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 20, 2022, 07:00 ET Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Jan 10, 2022, 07:00 ET Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones

David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on...

Dec 15, 2021, 07:00 ET Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Dec 13, 2021, 07:00 ET Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Dec 08, 2021, 07:00 ET Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Nov 10, 2021, 16:05 ET Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Aug 12, 2021, 16:05 ET Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

May 26, 2021, 07:00 ET Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

May 17, 2021, 17:00 ET Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Mar 11, 2021, 17:15 ET Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Mar 11, 2021, 07:00 ET Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...

Jan 08, 2021, 07:00 ET Nuvation Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel...

Oct 26, 2020, 08:30 ET Nuvation Bio Expands Executive Team with Appointment of Healthcare Investment Banking Leader Jennifer Fox as Chief Financial Officer

Nuvation Bio Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that...

Oct 13, 2020, 08:30 ET Nuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas

Nuvation Bio, Inc., an oncology company focused on revolutionizing cancer treatment by discovering, developing and delivering next-generation...

Oct 28, 2019, 08:00 ET Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds

Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an ...